Solodyn Antitrust Litigation
Solodyn Antitrust Litigation
Home
Home
Notice
Notice
Court Documents
Court Documents
Contact Information
Contact Information

The information contained on this website is only a summary. You may download a copy of the full Notice by clicking here.

 

 

If you purchased Solodyn or its generic version,
a class action lawsuit may affect your rights.

A court authorized this notice. This is not a solicitation from a lawyer.

 

A lawsuit is pending in the United States District Court for the District of Massachusetts (“the Court”) against the following Defendants: Medicis Pharmaceutical Corp., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. Plaintiffs in the lawsuit claim that Defendants hurt competition and violated state laws in the United States and its territories, including Puerto Rico. Plaintiffs allege Defendants unlawfully delayed the availability of allegedly less-expensive generic versions of Solodyn and that Defendants’ conduct caused certain consumers and third-party payors (discussed below) to pay too much for Solodyn in these states and territories. Defendants deny any wrongdoing.

On October 16, 2017, the Court determined that this case could proceed as a Class Action.

This lawsuit does not claim that Solodyn is unsafe or ineffective.

CERTIFIED CLASS

You may be a member of the Class if, during the period from July 23, 2009, until the alleged anticompetitive effects of Defendants’ allegedly unlawful conduct cease (the “Class Period”):

               As a Consumer, you purchased or paid for some or all of the purchase price for Solodyn 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg tablets and/or generic versions of one or more of these dosages, for consumption by yourself or your family, other than for resale, in Alabama, Alaska, Arizona, Arkansas, California, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming, the District of Columbia and Puerto Rico.

 

               As a Third-Party Payor, you purchased, paid and/or reimbursed for some or all of the purchase price for Solodyn 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg tablets and/or generic versions of one or more of these dosages, for consumption by your members, employees, insureds, participants, or beneficiaries, other than for resale, in Alabama, Alaska, Arizona, Arkansas, California, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming, the District of Columbia and Puerto Rico.

The following persons or entities are excluded from the End-Payor Class: (a) Defendants and their counsel, officers, directors, management, employees, subsidiaries, or affiliates; (b) All federal or state governmental entities, excluding cities, towns, or municipalities with self-funded prescription drug plans; (c) All persons or entities that purchased Solodyn or its generic equivalents for purposes of resale or directly from the Defendants or their affiliates; (d) Fully insured health plans (plans that purchased insurance from another third-party payor covering 100% of the plan’s reimbursement obligations to its members); (e) Pharmacy Benefits Managers; (f) Flat co-payers (consumers who paid the same co-payment amount for brand and generic drugs); and (g) The judges in this case and any members of their immediate families.

Please check this website for additional updates.

YOUR LEGAL RIGHTS AND OPTIONS

EXCLUDE YOURSELF
FROM THE CLASS

This option allows you to exclude yourself from the Class and instead file a lawsuit against the Defendants asserting claims related to the allegations or claims in this case. The exclusion deadline is February 10, 2018.

do nothing

Give up rights to be part of any other lawsuit that asserts claims related to the allegations or claims against the Defendants in this case.

adobe reader imageYou will need Adobe Reader to view documents on this site. You can learn more about Adobe Reader and download the latest version by clicking here.